Alpha Lipoic Acid Cognition Randomized Trial Evidence Table

Structured evidence table for Alpha Lipoic Acid Cognition Randomized Trial, generated from 1 reusable source document in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Alpha Lipoic Acid Cognition Randomized TrialObjectives This review aims to critically synthesize mechanistic, preclinical, and clinical evidence on α-lipoic acid and biotin as candidate neuroprotective agents in neurodegenerative diseases, with emphasis on shared signaling pathways, therapeutic potential, generally favorable safety profiles, and translational limitations.4Aguilera-Méndez A (2026)Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives.
Alpha Lipoic Acid Cognition Randomized TrialThe evidence was qualitatively analyzed with attention to biological plausibility, consistency across models, and clinical relevance.4Aguilera-Méndez A (2026)Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives.
Alpha Lipoic Acid Cognition Randomized TrialIn contrast, clinical evidence remains heterogeneous, with more extensive evaluation of biotin in progressive multiple sclerosis and more limited or exploratory findings for ALA across neurodegenerative disorders.4Aguilera-Méndez A (2026)Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives.
Alpha Lipoic Acid Cognition Randomized TrialBackground Neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis, represent a major global health burden and share convergent pathogenic mechanisms, such as mitochondrial dysfunction, oxidative stress, neuroinflammation, calcium imbalance, and neuronal loss.4Aguilera-Méndez A (2026)Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives.

Source documents

  1. Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives.